A Phase 1 Clinical Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of GS1-144 Tablets
Latest Information Update: 21 Feb 2025
At a glance
- Drugs GS1 144 (Primary)
- Indications Vasomotor symptoms
- Focus Adverse reactions
- Sponsors GeneScience Pharmaceuticals
Most Recent Events
- 11 Feb 2025 Status changed from recruiting to completed.
- 09 Dec 2024 Planned number of patients changed from 68 to 86.
- 09 Dec 2024 Planned End Date changed from 17 Dec 2024 to 17 May 2025.